SSA
ONCS

Schonfeld Strategic Advisors’s OncoSec Medical Incorporated ONCS Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ONCS Stock Details ONCS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,041
Closed -$11K – 3403
2022
Q3 		$11K Buy
1,041
+5
+0.5% +$75 ﹤0.01% 2733
2022
Q2 		$17K Hold
1,036
– – ﹤0.01% 2299
2022
Q1 		$26K Sell
1,036
-59
-5% -$1.25K ﹤0.01% 2382
2021
Q4 		$23K Sell
1,095
-60
-5% -$2.03K ﹤0.01% 1986
2021
Q3 		$55K Sell
1,155
-450
-28% -$22.8K ﹤0.01% 1998
2021
Q2 		$99K Sell
1,605
-295
-16% -$26.8K ﹤0.01% 1827
2021
Q1 		$199K Sell
1,900
-2,928
-61% -$401K ﹤0.01% 1513
2020
Q4 		$685K Buy
4,828
+3,560
+281% +$380K 0.01% 933
2020
Q3 		$95K Buy
+1,268
New +$98.9K ﹤0.01% 1276

Other funds holding ONCS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SM
Salzhauer Michael $292M AUM 30% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Schonfeld Strategic Advisors's ONCS Position: Q4 2022 in Review

Schonfeld Strategic Advisors sold out of OncoSec Medical Incorporated (ONCS) in Q4 2022, closing a stake of 1,041 shares — an estimated $11K sold.

Schonfeld Strategic Advisors first reported a position in ONCS in Q3 2020 and held it in 9 quarters. The position peaked at $685K in Q4 2020. 17 funds tracked by Wall St. Rank hold ONCS as of Q4 2022.

  • Schonfeld Strategic Advisors reported no remaining OncoSec Medical Incorporated position as of Q4 2022 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 1,041 OncoSec Medical Incorporated shares in Q4 2022, an estimated $11K.
  • Schonfeld Strategic Advisors first reported a position in OncoSec Medical Incorporated in Q3 2020 and held it in 9 quarters.
  • Schonfeld Strategic Advisors's OncoSec Medical Incorporated position peaked at $685K in Q4 2020.
  • 17 funds tracked by Wall St. Rank held OncoSec Medical Incorporated as of Q4 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.